rheumatoid arthritis

Showing 15 posts of 66 posts found.


GSK, Janssen RA treatment meets co-primary endpoints in Phase III trial

June 9, 2016
Research and Development GSK, Janssen, eular 2016, rheumatoid arthritis, sirukumab

GSK (LSE: GSK) and Janssen, a division of Johnson and Johnson, have announced data from a pivotal Phase III study …


Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars

April 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis

Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …


Lilly’s RA drug baricitinib meets Phase III goals

March 31, 2016
Research and Development Eli Lilly, Incyte, rheumatoid arthritis

Eli Lilly and Incyte have announced the publication of detailed Phase III trial results from a study of their biologic …

EMA to review Pfizer’s Xeljanz for patients with rheumatoid arthritis

March 24, 2016
Research and Development, Sales and Marketing EMA, Pfizer, Xeljanz, approval, authorisation, marketing, review, rheumatoid arthritis

Pfizer (NYSE: PFE) has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) …


Bristol-Myers Squibb to acquire Padlock Therapeutics for up to $600m

March 23, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, Padlock Therapeutics, rheumatoid arthritis

Bristol-Myers Squibb is to acquire Massachusetts-based auto-immune disease specialist Padlock Therapeutics in a deal worth up to $600 million. The …


Merck & Co says study shows significantly higher persistence for its arthritis drug Simponi

March 17, 2016
Research and Development, Sales and Marketing Merck & Co, drug trial, research, rheumatoid arthritis

US pharma giant Merck & Co (NYSE: MRK) said its rheumatoid arthritis drug showed significantly higher persistence compared with other drugs …


First Enbrel biosimilar launches in UK

February 16, 2016
Manufacturing and Production, Research and Development Enbrel, Samsung Bioepis, eternacept, rheumatoid arthritis

Following its approval by the European Commission in January, Benepali has become the first biosimilar of Pfizer/Amgen’s Enbrel (etanercept) to …

NICE backs biosimilars with arthritis drug endorsements

January 27, 2016
Research and Development, Sales and Marketing DMARDs, NICE, biosimilars, rheumatoid arthritis

NICE has published updated final guidance recommending seven biological disease modifying drugs (DMARDs) for treatment of severe rheumatoid arthritis which …


Lilly awaits FDA review of new arthritis treatment

January 20, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, FDA, Incyte, NDA, baricitinib, lilly, new drug application, rheumatoid arthritis

Eli Lilly has submitted a new drug application (NDA) to the FDA for baricitinib as a treatment for moderate-to-severe rheumatoid …

Baxalta logo

Baxalta’s Enbrel biosimilar measures up in late-stage study

January 13, 2016
Research and Development Amgen, Baxalta, Enbrel, Pfizer, biosimilar, etanercept, rheumatoid arthritis

Having emerged from its mega-merger deal with Shire, Baxalta is back on its drug development day job – and has …

AbbVie begins late stage trials of rheumatoid arthritis drug

January 11, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ABT-494, AbbVie, F-star, JAK-1 inhibitor, rheumatoid arthritis

AbbVie has begun a large phase III clinical trial programme for its next-generation rheumatoid arthritis (RA) treatment ABT-494, which the …

FDA sign

FDA review for Sanofi and Regeneron’s biologic arthritis drug

January 8, 2016
Medical Communications, Sales and Marketing FDA, Regeneron, Sanofi, biologics, rheumatoid arthritis, sarilumab

The FDA has accepted for review a Biologics License Application (BLA) from Sanofi and Regeneron for the rheumatoid arthritis treatment …

Gilead sign

Gilead steps in to rescue Galapagos RA drug

December 18, 2015
Sales and Marketing AbbVie, Gilead, Gilead Sciences, filgotinib, inflammation, inflammatory diseases, rheumatoid arthritis

Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …

Lilly/Incyte RA drug bests Humira in Phase III trial

November 10, 2015
Research and Development Humira, baricitinib, lilly, phase III, rheumatoid arthritis

Eli Lilly says its investigational therapy baricitinib outperformed AbbVie’s Humira after 12 weeks in a late-stage study of people with …

Sanofi image

Sanofi’s rheumatoid arthritis biologic performs

May 22, 2015
Sales and Marketing Sanofi, rheumatoid arthritis, sarilumab

French pharma giant Sanofi plans to submit its new rheumatoid arthritis biologic for regulatory approval in the US after it …

Latest content